Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease
AUTOR(ES)
Small, Gary W.
FONTE
The National Academy of Sciences
RESUMO
The major known genetic risk for Alzheimer's disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=18554Documentos Relacionados
- Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease.
- Current Concepts in Therapeutic Strategies Targeting Cognitive Decline and Disease Modification in Alzheimer’s Disease
- Alzheimer's disease: genetic variables and risk
- Genetic risk factors in Alzheimer's disease.
- Measurements of regional cerebral blood flow and cognitive performance in Alzheimer's disease.
